Reporting on what has been going on and why is one thing. Knowing what to do about it and when is another altogether.

Reporting on what has been going on and why is one thing. Knowing what to do about it and when is another altogether.
Everything we do at Libra is from ‘the bottom up.’ The sector and market signals are an aggregation from the signal stock level. Investors can start at the market level and cascade from sectors to stocks to see the best opportunities.
In the same way that many investment advisors failed to sell certain stocks when the time arose (see previous posts) they may not have the skillset or process that allows them gauge when to buy. In markets such as this, an answer is to be found in Benjamin Graham’s Margin of safety. The principle of […]
Knowing when to buy a stock is one thing but understanding the risk of loss is another skill altogether.
In May 2007 the sector traded at €200. During the GFC (Great Financial Crisis) the sector hit a low of €24 in March 2009 and from that moment until September 2023, the sector was an investor’s graveyard. In October 2022 Apollo deep value signals appeared equivalent to the GFC and Covid period. A Need to […]
As someone who has been around long enough to be following Tesco’s stock market journey since the late 1980’s I found myself bemused by the share price reaction to the news that Asda was on the verge of announcing a price war. Over the years we have got used to price wars, particularly the threat […]
Investors thought they had entered the year with complete clarity. US exceptionalism being just one of those factors. Last years winners would be this year’s winners etc. Sure, there would be change under Donald Trump’s presidency but no-one forecast what has happened and would happen and for investors, to use an excellent analogy the cockpit […]
Novo Nordisk (home to Ozempic) released results this morning have left the shares wallowing – 9.5% which now takes the shares down by -41% over the past 6 months. Those are the sort of numbers that only the Ozempic taking customers would be proud of if they applied to their waistlines. The writing has been […]
It’s been some time since I posted content from our Apollo EDGE platform but to those that follow our work, the Investment Cycle and Implied cost of capital model are key to understanding when stocks enter periods of change.In the images below you can see the Investment Cycle evolution over time. Nvidia entered a de-rating […]
A series of individual stock concerns in both the US and Europe – think Glaxo Smith Kline, Moderna, Astra Zeneca, Eli Lilly, Smith and Nephew, Merck and even Novo Norsdisk added to the fact that the new Trump administration may not be friendly for the sector has seen the sector in a Trump Slump.